UK markets closed

TC Biopharm (Holdings) Plc (TCBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.0400-0.0200 (-1.89%)
At close: 04:00PM EDT
1.0800 +0.04 (+3.85%)
After hours: 07:41PM EDT
Full screen
Loading interactive chart…
  • PR Newswire

    TCBP Announces Launch of Compassionate Use Program for TCB008

    TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the company's lead therapeutic TCB008 will be available to patients via a newly launched compassionate use program in the UK.

  • PR Newswire

    TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds

    TC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,750,000 of the Company's American Depositary Shares (the "ADSs") originally issued in December 2023 with an exercise price of £1.5814 per ADS and a term of five yea

  • PR Newswire

    TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies

    TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent to acquire a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies for the treatment of refractory cancers and solid tumors.